ViroPharma Incorporated
730 Stockton Drive
Exton
Pennsylvania
19341
United States
Tel: 610-458-7300
Fax: 610-458-7380
Website: http://www.viropharma.com/
Email: questions@viropharma.com
About ViroPharma Incorporated
ViroPharma Incorporated is a global biotechnology company dedicated to developing and commercializing products that help address dangerous, potentially life-threatening conditions such as hereditary angioedema (HAE), seizures in children and adolescents, and adrenal insufficiency. ViroPharma is headquartered in Exton, PA and has operations throughout Europe.ViroPharma’s core focus is on providing patients and physicians new therapeutic alternatives for today’s great unmet medical needs. ViroPharma has gained commercial approval for three important therapeutics in the United States or Europe, with several others in clinical development. For example, our product Cinryze (R) (C1 Esterase Inhibitor (human)) is indicated in the U.S. for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. In Europe, it is indicated for prophylaxis against HAE attacks, pre-procedure prophylaxis, and acute treatment of attacks of HAE in children and adolescents with HAE.
HAE is a rare inherited disorder which is characterized by painful swelling that can appear in various parts of the body. It most commonly affects the hands, feet, face, abdomen, urogenital tract, and upper respiratory tract. The inflammation can be disfiguring, debilitating, or in the case of laryngeal attack, life-threatening. If left untreated, HAE can result in a mortality rate as high as 40%, primarily due to upper airway obstruction or suffocation in undiagnosed patients.
ViroPharma is engaged in life-cycle management work with Cinryze on additional indications, formulations, and territories. In addition, our preclinical and clinical pipeline includes non-toxigenic C. difficile (NTCD), targeting prevention of recurrence of disease following therapy for acute C. difficile infection (CDI), a phase 1 compound targeting a rare disease called Friedreich's ataxia, several clinical and investigator initiated studies of C1 esterase inhibitor in diseases mediated by the complement cascade, and our Phase 2 agent called maribavir, targeting transplant-associated cytomegalovirus (CMV) infection.
Through the success ViroPharma’s products and our management team’s savvy business model, the company’s is well positioned financially to continue to add new products that will provide hope to physicians treating patients with unmet medical needs.
ViroPharma is an equal opportunity employer and promotes diversity throughout its organization. A strong foundation of shared values among the people of ViroPharma, brought together with a clear and common purpose, has contributed to the culture of ViroPharma. The company is seeking individuals with the skills and passion for results to join the ViroPharma team as part of the catalyst to future success. In addition to a rewarding work environment emphasizing teamwork, commitment and communication, ViroPharma provides competitive salaries, medical/dental benefits, a 401(k) plan and stock options.
Please visit ViroPharma’s Online Recruitment Center to complete a profile and apply.
284 articles about ViroPharma Incorporated
-
Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors
6/7/2018
Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.
-
FTC Sues Shire ViroPharma for Using Illegal Tactics to Block Generic Competition
2/8/2017
-
$4.2 Billion Deal Gives ViroPharma Incorporated Execs Huge Paydays
2/10/2014
-
Shire plc Extends Tender Offer For ViroPharma Incorporated, Acceptances Up To 76 Percent
12/27/2013
-
Hart-Scott-Rodino Waiting Period Expires for Shire's Acquisition Of ViroPharma Incorporated
12/11/2013
-
Shire plc's Acquisition Of ViroPharma Incorporated Will Add $831 Million In Revenue By 2018, Says GlobalData
11/18/2013
-
ViroPharma Incorporated Release: Analysis Of Pivotal Study Data Showed Routine Prevention Of Hereditary Angioedema (HAE) Attacks With Cinryze® (C1 Esterase Inhibitor [Human]) Resulted In Improved Health-Related Quality Of Life Outcomes Compared To Acute T
11/12/2013
-
Shire To Pay $4.2 Billion For Rare Disease Firm ViroPharma Incorporated
11/11/2013
-
ViroPharma Incorporated Announces Upcoming Data Presentations at the 2013 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting
11/7/2013
-
ViroPharma Incorporated Reports Third Quarter 2013 Financial Results
10/31/2013
-
ViroPharma Incorporated to Release 2013 Third Quarter Financial Results on October 31, 2013
10/28/2013
-
ViroPharma Incorporated to Participate in the Leerink Swann and Company Rare Disease Conference
9/27/2013
-
ViroPharma Incorporated Drug Appeal Seen Driving 50% Return: Real M&A
9/23/2013
-
ViroPharma Incorporated Said to Hire Goldman, Sachs & Co. Amid Sanofi (France), Shire plc Interest
9/16/2013
-
ViroPharma Incorporated to Participate in the Stifel Nicolaus 2013 Healthcare Conference
9/10/2013
-
Halozyme Therapeutics, Inc. Plummets as Its Partner ViroPharma Incorporated Discontinues Phase 2 Trial
8/2/2013
-
ViroPharma Incorporated Announces Second Quarter 2013 Financial Results
8/1/2013
-
ViroPharma Incorporated to Release 2013 Second Quarter Financial Results on August 1, 2013
7/25/2013
-
ViroPharma Incorporated to Participate in the JMP Securities 2013 Healthcare Conference
7/1/2013
-
ViroPharma Incorporated Provides Update From Ongoing Phase 2 Studies of Maribavir for Treatment of Cytomegalovirus (CMV) Infections
6/28/2013